Skip to main content

Arcascience

Category: AI in Healthcare

An AI-powered healthtech company providing benefit-risk intelligence to accelerate and de-risk drug development. Arcascience was founded in 2021. The company is led by Romain Clément. Based in Paris, France. Team size: 11-50. Total funding raised: $7 million. Latest round: Seed, $7.0M, 2025-09, led by The Moon Venture. Key investors include The Moon Venture, Pléiade Venture, Plug & Play Ventures, Bpifrance, AKKA Technologies.

Founded
2021
Headquarters
Paris, France
Team size
11-50
Total funding
$7 million

Value proposition

To accelerate drug development and reduce R&D costs by providing a continuous, AI-driven benefit-risk analysis of drugs, shortening the evaluation phase by up to 18 months.

Products and solutions

AI-native Benefit-Risk Analysis (BRA) platform

Unique value

Arcascience offers what it claims to be the only AI-native platform for Benefit-Risk Analysis (BRA). Unlike traditional methods, it continuously tracks and analyzes drug data from a vast range of structured and unstructured biomedical sources, providing real-time insights.

Target customer

Pharmaceutical companies, the biopharma industry, and Contract Research Organizations (CROs).

Industries served

Pharmaceuticals, Biotechnology Research, Healthcare

Technology advantage

The company's core advantage lies in its proprietary technology, which includes 23 specialized AI models that hybridize LLMs and encoder-based infrastructures. This system processes a database of over 100 billion health data points to deliver its analyses.

How they differentiate

Arcascience differentiates itself through its AI-powered benefit-risk intelligence platform that continuously tracks and analyzes vast amounts of biomedical data, including clinical research, scientific literature, and real-world patient-centric sources. This allows them to provide early predictions on a drug candidate's success, de-risking and accelerating the development process for pharmaceutical companies.

Main competitors

IQVIA, Parexel, Thermo Fisher

Key partnerships

Sanofi, AstraZeneca, GSK, Takeda, ICON, Paris Brain Institute, A pan-European consortium for pediatric brain cancer

Notable customers

Sanofi, AstraZeneca, GSK, Takeda, ICON, Paris Brain Institute

Major milestones

Secured a $7 million seed funding round to fuel expansion into the US and UK., Selected by the French government during the COVID-19 crisis to structure and analyze the complete corpus of scientific knowledge on the virus., Named one of the top 10 European healthtech companies in the international Healthtech Challengers contest., Became a member of a pan-European consortium, initiated by Sanofi, to use AI in combating pediatric brain cancer.

Growth metrics

The company has shown significant early traction, reporting over 700% growth in four months and signing $1.2 million in contracts. Specific client contract growth includes Sanofi increasing from $90K to $540K/year and ICON from $10K to $600K/year.

Market positioning

Arcascience is positioned as a specialized AI-first healthtech company focused on the early stages of drug development. They provide predictive analytics and benefit-risk assessment tools to help biopharma companies make smarter, data-driven decisions, thereby reducing the high failure rates and costs associated with pharmaceutical R&D.

Geographic focus

Arcascience is headquartered in Paris, France, with a primary focus on the European market. They are actively expanding their operations into the United States and the United Kingdom.

Patents and IP

Information on specific patents is not publicly available.

About Romain Clément

Romain Clément is the Co-founder and CEO of Arcascience. He holds a Master's degree in Digital Publishing from Sorbonne Université and has a background in scientific data management and digital editorial consulting. His personal experience with brain cancer was a primary motivator for founding Arcascience to improve the benefit-risk assessment of drugs.

Official website: